[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rsv-immunization\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rsv-immunization":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,40,62,95,119,150],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100640630","rsv-immunisation-status-in-queensland-australia-100640630",false,"NCT07615192","RSV Immunisation Status in Queensland (Australia)","Inclusion Criteria:\n\n* Be a parent of an infant born between 1 February 2024 and 15 April 2025\n* Be at least 18 years of age\n* Reside in Queensland, Australia\n* Read and agree to the Participant Information and Consent Form (PICF) before proceeding to the survey\n* Agree with Adverse Event (AE) reporting requirements before proceeding to the survey\n\nExclusion Criteria:\n\n\\- Have participated in any studies on infant respiratory diseases in the past 4 months\n\nThe above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.",true,"ALL","18 Years",{"count":19,"type":20},1200,"ESTIMATED","OBSERVATIONAL","The primary objective of this study is to determine the nirsevimab immunisation rate in eligible infants (according to Queensland Paediatric Respiratory Syncytial Virus Prevention Program recommendation) in Queensland, Australia.\n\nThe study will focus on:\n\n1\\. Assessing the immunisation rates among eligible infants (born from 1 February 2024 to 15 April 2025) in their first Respiratory Syncytial Virus (RSV)-season in Queensland.\n\nSecondary objectives of this study are as follows:\n\n1. To analyse reasons of parents to decide for or against immunisation of their infant with nirsevimab.\n\n   1. This objective aims to assess potential influencing factors and evaluate the changes in acceptance across the three cohorts prior and post recommendation.\n   2. In this regard, demographic factors (e.g. education, income) will be included in the analysis where applicable to gain insights on their potential impact.\n2. To assess immunisation rates for further subgroups, e.g. by: a) risk group (defined chronic condition or pre-term birth status), b) regional areas of Queensland.\n3. To compare the vaccination coverage rate estimates with data captured via the Australian Immunisation Register.",[24],"RSV Immunization",[26],"nirsevimab; nirsevimab immunization rates","RECRUITING","2026-06-22",{"date":30,"type":31},"2026-06-23","ACTUAL",{"date":33,"type":31},"2026-05-29",{"date":35,"type":20},"2026-07-20",{"name":37,"class":38},"Sanofi","INDUSTRY",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":48,"conditions":49,"keywords":50,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":39},"100643183","an-observational-study-to-assess-nirsevimab-immunization-rates-in-eligible-infants-during-their-first-rsv-season-in-the-czechia-100643183","NCT07634692","An Observational Study to Assess Nirsevimab Immunization Rates in Eligible Infants During Their First RSV Season in the Czechia","Inclusion Criteria:\n\n* Be a parent of an infant born between April 2025\u002F26 and March 2026\u002F27, respectively\n* Permanent residence in Czechia at the time of survey completion and speak Czech\n* Be at least 18 years old at the time of survey completion\n* Agree with privacy policy and AE (Adverse Event) reporting requirements before proceeding with the survey\n* Read and agree to the ICF (Informed Consent Form) by ticking a box before proceeding with the survey\n\nExclusion criteria:\n\n* N\u002FA\n\nThe above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.",{"count":47,"type":20},250,"The primary objective of this study is to determine the nirsevimab immunization rate in eligible infants in their first RSV-season in Czechia.\n\nThe study will focus on:\n\n1. Assessing nirsevimab immunization rates among eligible infants (according to ČVS recommendation) in their first RSV-season in Czechia (i.e. across all geographies)\n2. Assessing nirsevimab immunisation rates among the \"catch-up cohort\", i.e. all infants born between April and September.\n3. Assessing nirsevimab immunization rate among the \"in-season cohort\", i.e. all infants born during the RSV season between October and March.\n\nSecondary objectives are:\n\n1. To analyze reasons of parents to decide for or against immunization of their infant with nirsevimab.\n2. To assess immunization rates for further subgroups, if sufficient sample for subgroup achieved, e.g. by: risk group (defined chronic condition or pre-term birth status)\n3. To assess concordance of a parent survey results based on randomly sampled parent population using Computer-Assisted Self-Interviewing (CASI) for estimating immunization rates in Czechia with coverage calculated based on pharmacy sales data.",[24],[51,52],"nirsevimab;","nirsevimab immunization rates","NOT_YET_RECRUITING","2026-06-03",{"date":56,"type":31},"2026-06-09",{"date":58,"type":20},"2026-06-15",{"date":60,"type":20},"2026-07-17",{"name":37,"class":38},{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":77,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":39},"100610832","phase-3-prevention-of-rsv-infection-in-infants-by-administering-nirsevimab-to-infants-with-or-without-maternal-rsv-vaccination-100610832","NCT07232706","Prevention of RSV Infection in Infants by Administering Nirsevimab to Infants, With or Without Maternal RSV Vaccination","Prevention of RSV Infection in Infants by Administering Nirsevimab to Infants, With or Without Maternal RSV Vaccination: a Randomised Controlled Trial in France as Part of the Pregnancy and Infant PrEparedness pLatform IN Europe - PIPELINE","PIPELINE-RSV-F","Inclusion Criteria:\n\n1. Pregnant women\n2. Provide informed consent prior to study enrolment\n3. Willing and able (in the site investigator's opinion) to comply with all study requirements\n4. More than 18 years of age\n5. Between 32 and 36 weeks of gestation\n6. Able to read and complete the eHealth questionnaire in French or English\n7. Willing to receive maternal vaccine in pregnancy, if allocated\n8. Willing for the baby to receive infant nirsevimab\n9. Willing for their data to be re-used as part of the joint analysis with PIPELINE-RSV-International trial\n10. Affiliated to social security regime or an equivalent system\n\nInclusion Criteria - Infants:\n\n1. Live-birth to mother enrolled in the study\n2. Informed consent from the mother, and the other legal representative (partner \u002F co-parent) when applicable\n\nExclusion Criteria:\n\n1. Major illness of the maternal participant or conditions of the foetus that, in the investigator's judgment, would substantially increase the risk associated with the maternal or infant participant's participation in and completion of the study\n2. Any suspected or confirmed condition in the foetus that in the opinion of the site investigator would contraindicate participation of the future newborn\u002Finfant in the study\n3. High risk of prematurity as judged by treating clinician\n4. Multiple pregnancy (i.e. twins, triplets or more)\n5. Previous participation in the PIPELINE-RSV trial\n6. Receipt of any previous RSV prevention product in this pregnancy or currently participating in another interventional RSV prevention trial\n7. Any contraindication for receipt of intramuscular injection (bleeding diathesis or a condition associated with prolonged bleeding) or of vaccine (history of severe allergic reaction (e.g. anaphylaxis) to any component of the vaccine)\n8. History of Guillain Barré Syndrome (GBS)",{"count":71,"type":20},1000,"INTERVENTIONAL",[74],"PHASE3","RSV (which stands for Respiratory Syncytial Virus) is an infection that causes cold-like symptoms and is most common during winter months. Most people with RSV infection get better by themselves but babies and younger children can become very poorly. About 1 in 15 infants with confirmed RSV within the first 12 months of life will be hospitalised, and a very small proportion will be seriously ill and may die.\n\nCurrently there are two different prevention options that can be used to prevent RSV infection in babies. One is a vaccine given to the mother during pregnancy, and the other is a monoclonal antibody given by injection to the baby. Although both prevention options work well on their own and are safe, neither provides 100% protection to the infant. It is not known whether giving both medicines, one to the mother in pregnancy and one to the infant, would provide better protection than giving only one medicine - this is what the PIPELINE-RSV study will look at.\n\nPIPELINE-RSV-France will recruit about 1000 pregnant women in France. A parallel trial, running across Europe (PIPELINE-RSV-International) will recruit about 1500 pregnant women in UK, Switzerland, the Netherlands and Belgium. The protocols will align on key aspects and the data will be analysed together. The study will include two study groups with different prevention options used in each: (1) an injection given to the baby at the beginning of RSV season, or (2) both a vaccine given to the mother in pregnancy and an injection given to the baby at around 4 months of age. Each mother-baby pair will be randomly allocated to group by a computer. The numbers of babies in each of these groups who acquire RSV will be compared. In some countries participating to the International trial, an other study groups may be available : (3) a vaccine given to the mother in pregnancy.\n\nPregnant women and their babies will be followed until the baby reaches 12 months of age. Information will be collected about medically-important side effects either the mother or the baby had from their medicine(s) and any symptoms of RSV the baby had. Visits with the mother and baby will occur at birth and 12 months later. The mother will complete questionnaires via a Web-based platform to report any non-routine in-person visits, once in pregnancy and after the baby is born twice a month or monthly (more often in the winter), to also report baby's symptoms, to report their trial experience when the baby is 4 and 12 months' old, and to provide their views on vaccination at birth, and when the baby is 4 and 12 months' old. If the baby develops symptoms that might be RSV, their mother or another caregiver will be asked to take a sample using a swab from the baby's nose or mouth, and to send it by post for testing to find out if the baby has RSV.\n\nAs well as the main research study, there are also some substudies. A questionnaire will be given to women who consent to take part, to find out their motivations for joining the study and how they prefer to receive information about taking part in studies. A small number of women will be asked to take part in a study to look at how mothers' and babies' immune systems respond to the two different study prevention options , and to investigate different ways of collecting samples from their babies. In addition, researchers will use data from the study to see whether giving both medicines is cost-effective compared with giving just one medicine.",[24],[78,79,80,81,82,83,84],"nirsevimab","abrysvo","rsv","respiratory infection","Respiratory Syncytial Virus","prevention","immunization","2026-05-22",{"date":87,"type":31},"2026-05-27",{"date":89,"type":31},"2026-05-06",{"date":91,"type":20},"2029-05-05",{"name":93,"class":94},"Centre Hospitalier Annecy Genevois","OTHER",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":72,"phases":104,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":39},"100615708","phase-4-rsv-vaccine-response-in-stem-cell-and-car-t-therapy-recipients-100615708","NCT07296120","RSV Vaccine Response in Stem Cell and CAR-T Therapy Recipients","Seroconversion Following RSV Vaccination in Bone Marrow Transplant and CAR-T Patients","Inclusion Criteria:\n\n* Age 18 years or older\n* Diagnosis of hematological malignancy\n* Treatment with HSCT or CAR-T therapy\n* Must be able to give informed consent\n* Must be willing to provide blood samples after HSCT or CAR-T therapy and prior to vaccination\n* Must be willing to provide blood samples at four weeks and six months post-vaccination\n* Must have an insurance plan that covers the cost of recieving the RSV vaccine.\n\nExclusion Criteria:\n\n* History of a severe allergic reaction to any component of the RSV vaccine\n* Use of intravenous immunoglobulin (IVIG) for hypogammaglobulinemia within the past six months",{"count":103,"type":20},30,[105],"PHASE4","This study evaluates whether the RSV vaccine Abrysvo can produce an antibody response in patients with blood cancers who have previously received a hematopoietic stem cell transplant (HSCT) or CAR-T cell therapy. The vaccine targets the prefusion F (preF) protein of RSV, which is an important component of protective immunity against the virus.\n\nThe main goal of the study is to measure the change in antibody levels against the preF protein four weeks after vaccination compared with levels before vaccination. The study will also assess whether participants develop a meaningful immune response, defined as at least a four-fold increase in RSV neutralizing antibody levels four weeks after vaccination.",[108,24,109],"CAR-T Cell Therapy","Bone Marrow Transplant - Autologous or Allogeneic","2025-12-18",{"date":112,"type":31},"2025-12-22",{"date":114,"type":20},"2026-01-01",{"date":116,"type":20},"2027-06-30",{"name":118,"class":94},"The Cooper Health System",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":72,"phases":128,"briefSummary":130,"conditions":131,"keywords":135,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":39},"100606101","a-study-to-evaluate-community-based-measures-to-increase-rsv-vaccine-use-among-latino-adults-100606101","NCT07171164","A Study to Evaluate Community-Based Measures to Increase RSV Vaccine Use Among Latino Adults","Motivate Vaccinate Activate: An Effectiveness-Implementation Trial to Assess the Impact of a Multi-Component Community-Based Intervention to Increase RSV Vaccine Uptake Among Latino Older Adults","Motivate Aim Inclusion Criteria:\n\n* Age 50 years or older\n* Self-identify as Latino\u002Fa\u002Fx and\u002For indigenous groups from Latin America\n* Eligible for RSV vaccination per current CDC\u002FACIP recommendations\n* Fluent in Spanish or English\n* Has not received the RSV vaccine\n* Has a cell phone\n* Lives or works in San Francisco or Daly City\n* Able to provide informed consent\n\nMotivate Aim Exclusion Criteria:\n\n* Intent to move outside of San Francisco or Daly City in the next year\n* Nursing home resident\n* Household member participating in Aim 1 or 2\n* Unable to provide consent\n\nMotivate Aim Inclusion Criteria:\n\n* Age 18-49 years\n* Self-identify as Latino\u002Fa\u002Fx and\u002For indigenous groups from Latin America\n* Fluent in English or Spanish\n* Has \\>1 family member or friend 50 years or older who they have seen or spoken to for \\>15 minutes in the last 6 months and who lives in the United States\n\nActivate Trial Exclusion Criteria:\n\n* Household member enrolled in Aim 1 or 2\n* Unable to provide consent",{"count":127,"type":20},750,[129],"NA","In collaboration with community-based organizations, this study will focus on increasing RSV vaccine use among Latinos. The study will determine how effective community health worker counseling and text-message approaches are to (1) increase RSV vaccine use among older adults (Motivate phase) and (2) encourage younger adults to discuss RSV vaccination with their older friends and family members (Activate phase).",[132,133,24,134],"Older Adults Without Any Specific Clinical Condition","Social Networks","Vaccine Uptake",[136,137,138,139,140],"RSV","RSV vaccine","Social networks","Counseling","Healthy adults","2025-09-24",{"date":143,"type":31},"2025-09-30",{"date":145,"type":31},"2025-09-10",{"date":147,"type":20},"2028-11",{"name":149,"class":94},"University of California, San Francisco",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":15,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":72,"phases":160,"briefSummary":161,"conditions":162,"keywords":163,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":4},"100596110","phase-3-pregnancy-and-infant-preparedness-platform-in-europe-rsv-international-adaptive-platform-trial-to-evaluate-two-approved-prevention-options-to-prevent-respiratory-syncytial-virus-in-infants-maternal-vaccine-to-women-in-pregnancy-and-monoclonal-antibody-to-the-infants-given-alone-or-in-combination-100596110","NCT07041190","Pregnancy and Infant PrEparedness pLatform IN Europe, RSV-International Adaptive Platform Trial to Evaluate Two Approved Prevention Options to Prevent Respiratory Syncytial Virus in Infants: Maternal Vaccine to Women in Pregnancy and Monoclonal Antibody to the Infants, Given Alone or in Combination.","PIPELINE-RSV International Trial. Pregnancy and Infant PrEparedness pLatform IN Europe (PIPELINE)- RSV International Immunisation Adaptive Platform Trial.","PIPELINE-RSV","Inclusion Criteria:\n\n* Pregnant women\n\n  * Pregnant woman #\n  * Provide informed consent prior to study enrolment\n  * Willing and able (in the Site Investigator's opinion) to comply with all study requirements\n  * Above the national legal age of consent\n  * Between 24+0 (or later as per national guidance) and 36+6 weeks gestation\n  * Able to read and complete the eHealth questionnaire in a language in which it is available\n  * Willing to receive MV in pregnancy, if allocated\n  * Willing for the baby to receive infant mAb, if allocated\n\nInfant\n\n* Informed consent provided by the mother, and other infant legal representative (partner \u002F co-parent) or legal guardian(s) if required by local regulations\n* Live-birth to mother enrolled in the study\n\n  * Inclusive of pregnant person of any\u002Fno gender\n\nExclusion Criteria:\n\nPregnant women\n\n* Major illness of the maternal participant or condition of the foetus that in the opinion of the Site Investigator would substantially increase the risk associated with the woman's participation in and completion of the study\n* Any suspected or confirmed condition in the foetus that in the opinion of the Site Investigator would contraindicate participation of the infant in the study\n* High risk of prematurity as judged by treating clinician\n* Multiple pregnancy (i.e. twins, triplets or more)\n* Previous participation in the PIPELINE-RSV trial\n* Receipt of any previous RSV prevention product in this pregnancy or currently participating in another interventional RSV prevention trial\n* Any contraindication for receipt of intramuscular injection (bleeding diathesis or a condition associated with prolonged bleeding) or of vaccine (history of severe allergic reaction, e.g., anaphylaxis, to any component of the vaccine)\n* History of Guillain Barre Syndrome\n\nNote, all live born infants to mothers participating in the study will be included (with consent as required), but infant mAb will not be given if contraindicated.",{"count":159,"type":20},1500,[74],"RSV (which stands for Respiratory Syncytial Virus) is an infection that causes cold-like symptoms and is most common during winter months. Most people with RSV infection get better by themselves but babies and younger children can become very poorly. About 1 in 15 infants with confirmed RSV within the first 12 months of life will be hospitalised, and a very small proportion will be seriously ill and may die.\n\nCurrently there are two different prevention options that can be used to prevent RSV infection in babies. One is a vaccine given to the mother during pregnancy, and the other is a monoclonal antibody given by injection to the baby. Although both prevention options work well on their own and are safe, neither provides 100% protection to the infant. It is not known whether giving both medicines, one to the mother in pregnancy and one to the infant, would provide better protection than giving only one medicine - this is what the PIPELINE-RSV study will look at.\n\nPIPELINE-RSV-International will recruit about 1500 pregnant women from across Europe in UK, Switzerland, the Netherlands and Belgium. A parallel trial, PIPELINE-RSV-France, running in France will recruit about 1000 pregnant women in France; the protocols will align on key aspects and the data will be analysed together. The study will include three study groups with different prevention options used in each: (1) a vaccine given to the mother in pregnancy, (2) an injection given to the baby at the beginning of RSV season, or (3) both a vaccine given to the mother in pregnancy and an injection given to the baby at around 4 months of age. Each mother-baby pair will be randomly allocated to group by a computer. The numbers of babies in each of these groups who acquire RSV will be compared. In some countries only two of the three study groups may be available.\n\nPregnant women and their babies will be followed until the baby reaches 12 months of age. Information will be collected about medically-important side effects either the mother or the baby had from their medicine(s) and any symptoms of RSV the baby had. Visits with the mother and baby will occur at birth, and 4 and 12 months later; these will ideally be in-person at birth and at 12 months. The mother will complete questionnaires via a Web-based platform to report any non-routine in-person visits, once in pregnancy and after the baby is born twice a month or monthly (more often in the winter), to also report baby's symptoms, to report their trial experience when the baby is 4 and 12 months' old, and to provide their views on vaccination at birth, and when the baby is 4 and 12 months' old. If the baby develops symptoms that might be RSV, their mother or another caregiver will be asked to take a sample using a swab from the baby's nose or mouth, and to send it by post for testing to find out if the baby has RSV.\n\nAs well as the main research study, there are also some substudies. A questionnaire will be given to women who consent to take part, to find out their motivations for joining the study and how they prefer to receive information about taking part in studies. A small number of women will be asked to take part in a study to look at how mothers' and babies' immune systems respond to the two different study prevention options , and to investigate different ways of collecting samples from their babies. In addition, researchers will use data from the study to see whether giving both medicines is cost-effective compared with giving just one medicine.\n\nThe study might be adapted in the future to look at other medicines for preventing RSV infection, when they become available.",[24],[164,165],"Pregnancy RSV Immunization","Infant RSV Immunization","2025-06-19",{"date":168,"type":31},"2025-06-27",{"date":170,"type":20},"2025-09",{"date":172,"type":20},"2028-12",{"name":174,"class":175},"PENTA Foundation","NETWORK"]